Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 14, 2005; 11(42): 6571-6576
Published online Nov 14, 2005. doi: 10.3748/wjg.v11.i42.6571
Published online Nov 14, 2005. doi: 10.3748/wjg.v11.i42.6571
A | B | C | |
Ascites | None | Controlled | Uncontrolled |
Bilirubin (mmol/L) | <2.0 | 2.0-2.5 | >3.0 |
Encephalopathy | None | Minimal | Advanced |
PT (s prolonged) | <4.0 | 4.0-6.0 | >6.0 |
INR | <2.0 | 2.0-3.0 | >3 |
Albumin (g/L) | >3.5 | 3.0-3.5 | <3.0 |
Retroviruses | Adenoviruses | Adeno-associated virus (AAV) | Herpes virus |
8kb, RNA enveloped | 35 kb, DNA, non-enveloped | 5 kb, single stranded DNA, non-enveloped | 61 kb, double-stranded DNA |
Activate proto-oncogene by insertional mutagenesis | Episomal, transient | Stable integration, high infectivity | Infect mainly neurons |
Cause lymphoma | Highly immunogenic, causing inflammation and anaphylactic shock | Non-pathogenic; requires helper viruses such as Adenoviruses for replication and packaging in mammalian cells. | Cause cold sores or blisters in the genital areas |
Inactivation of transgene in vivo | One case of death | Long-term expression in vivo | Cutaneous skin lesions |
- Citation: Chiriva-Internati M, Grizzi F, Jumper CA, Cobos E, Hermonat PL, Frezza EE. Immunological treatment of liver tumors. World J Gastroenterol 2005; 11(42): 6571-6576
- URL: https://www.wjgnet.com/1007-9327/full/v11/i42/6571.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i42.6571